BIO-IMAGING TECHNOLOGIES, INC. ANNOUNCES CONTRACT WITH DIATIDE, INC.
WEST TRENTON, N.J., March 25 /PRNewswire/ -- Bio-Imaging Technologies, Inc. (OTC Bulletin Board: BITI), announced today that it has entered into an agreement with Diatide, Inc. (Nasdaq: DITI) to provide medical image core laboratory and digital image management services to support a Phase IV Study of ACUTECT(TM) in Patients With Acute Deep Vein Thrombosis and Patients With Post Phlebitic Syndrome.
For the study, Bio-Imaging will be responsible for site set-up and standardization, image data collection, centralized image data translation and standardization, image quality control and the conduct of masked reading of the image data.
Mr. Mark L. Weinstein, president and chief executive officer of Bio- Imaging Technologies said, "Our focus on broadening our customer base is beginning to show results. We are excited to be working with Diatide on the further development of this agent and look at this as the start of a long and mutually beneficial relationship. We are committed to providing high quality services and exceeding customer expectations in order to build solid client relationships."
Diatide, Inc., located in Londonderry, New Hampshire, is a specialty pharmaceutical company engaged in the discovery and development of proprietary disease-specific radiopharmaceuticals for the diagnosis and treatment of life- threatening conditions such as cancer, infection and cardiovascular disease.
Bio-Imaging Technologies, Inc. is a pharmaceutical contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its Corporate headquarters (West Trenton, NJ), U.S. Business Offices (New Jersey, Massachusetts and California) and its European office (Leiden, The Netherlands).
Certain matters discussed in this press release are "forward-looking
statements" intended to qualify for the safe harbors from liability
established by the Private Securities Litigation Reform Act of 1995.
In particular, the Company's statements regarding trends in the
marketplace and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the timing of
projects due to the variability in size, scope and duration of
projects, regulatory delays, clinical study results which lead to
reductions or cancellations of projects, and other factors, including
general economic conditions and regulatory developments, not within the
Company's control. The factors discussed herein and expressed from
time to time in the Company's filings with the Securities and Exchange
Commission could cause actual results and developments to be materially
different from those expressed in or implied by such statements. The
forward-looking statements are made only as of the date of this press
release and the Company undertakes no obligation to publicly update
such forward-looking statements to reflect subsequent events or
circumstances.
SOURCE Bio-Imaging Technologies, Inc.
-0- 03/25/99 /CONTACT: Robert J. Phillips, Chief Financial Officer of Bio-Imaging Technologies, 609-883-2000, ext. 226/
/Web site: http://www.bioimaging.com/ (BITI DITI) CO: Bio-Imaging Technologies, Inc.; Diatide, Inc. ST: New Jersey, New Hampshire IN: CPR MTC SU: CON